| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |